消癌平注射液联合NP方案治疗晚期NSCLC临床观察.docVIP

消癌平注射液联合NP方案治疗晚期NSCLC临床观察[摘要] 目的：观察消癌平注射液联合NP方案治疗晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的临床疗效。方法：选择晚期NSCLC患者60例，分为NP方案联合消癌平注射液组（治疗组）30例及单纯NP化疗组30例（对照组），两组治疗前均未行放化疗。结果：治疗组缓解率优于对照组，差异有统计学意义（P＜0.05）；两组在临床症状、生活质量、消化道反应及骨髓抑制等方面，治疗组均优于对照组（均P＜0.05）。结论：消癌平注射液联合NP方案治疗NSCLC的疗效较好，能稳定病灶，有效改善临床症状，提高生存质量及降低不良反应。 [关键词] 消癌平注射液；NSCLC；化疗 [中图分类号] R734.2 [文献标识码]A [文章编号]1673-7210（2011）03（b）-064-02 Effect of Xiaoaiping Injection combined with NP regimen in the treatment of advanced non-small cell lung cancer YANG Hong, LU Shuang, WANG Jue, ZHANG Cuiying Department of Medical Oncology, Inner Mongolia Hospital, Huhehaote 010017, China [Abstract] Objective: To observe Xiaoaiping Injection combined with NP regimen in treatment of advanced non-small cell lung cancer (NSCLC). Methods: 60 cases of advanced non-small cell lung cancer were divided into Xiaoaiping Injection combined with NP regimen group (treatment group) 30 cases and simple 30 cases of NP regimen group (control group), two groups during treatment did not line radiotherapy and chemotherapy. Results: The remission of lesions in treatment group was higher than that of the control group (P＜0.05). Clinical symptoms, quality of life, the gastrointestinal reactions andmyelosuppression of treatment group all were better than those of control group (all P＜0.05). Conclusion: Xiaoaiping Injection in combination with NP regimen in treatment of non-small cell lung cancer has better efficacy, the stability of lesions, effectively improves the clinical symptoms and improves quality of life and less adverse reaction. [Key words] Xiaoaiping Injection; Non-small cell lung cancer; Chemotherapy 肺癌是世界上发病率及死亡率最高的恶性肿瘤，非小细胞肺癌（non-small cell lung caner，NSCLC）约占80%，2/3以上NSCLC患者确诊时已属晚期，失去了手术机会[1]，只能进行全身化疗为主的综合治疗，这样可以延长生存期，缓解症状，提高生活质量。临床中，笔者通常采取用第三代化疗新药得到的整体有效率徘徊在28%～35%[2]，但化疗伴随的各种毒副作用也是临床中困扰医生与患者的重要问题。我科采用消癌平注射液联合NP方案治疗非小细胞肺癌取得了较好的临床疗效，现报道如下： 1 资料与方法 1.1 一般资料 60例晚期NSCLC患者均为我科2008年1月～2010年10月间住院患者，年龄39～77岁，平均62.5岁；经病理学或细